Skip to main content

Market Overview

H.C. Wainwright Initiates Stemline Therapeutics With Buy

Share:

H.C. Wainwright initiated coverage on Stemline Therapeutics Inc (NASDAQ: STML) with a Buy rating.

The target price for Stemline Therapeutics is set to $38.

Stemline Therapeutics shares have gained 16.51 percent over the past 52 weeks, while the S&P 500 index has surged 13.28 percent in the same period.

Stemline Therapeutics' shares fell 2.47 percent to close at $16.58 on Friday.

Latest Ratings for STML

DateFirmActionFromTo
May 2020WedbushDowngradesOutperformNeutral
May 2020Ladenburg ThalmannDowngradesBuyNeutral
May 2020HC Wainwright & Co.DowngradesBuyNeutral

View More Analyst Ratings for STML
View the Latest Analyst Ratings

 

Related Articles (STML)

View Comments and Join the Discussion!

Posted-In: H.C. WainwrightInitiation Analyst Ratings

Latest Ratings

StockFirmActionPT
GOOGLMizuhoMaintains2,600.0
VZIOWells FargoInitiates Coverage On31.0
TWTROppenheimerMaintains85.0
SBUXOppenheimerMaintains135.0
OMWells FargoInitiates Coverage On63.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
SPAC
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com